Uncategorized
European Commission grants orphan drug designation to GenSight’s retinitis pigmentosa treatment
GenSight Biologics announced the European Commission granted orphan drug designation to product candidate GS030 for the treatment of retinitis pigmentosa. The commission granted the designation based on a favorable recommendation from the European Medicines Agency. The EMA also granted advanced therapy medicinal product classification to GS030, according to a company press release.